These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

427 related items for PubMed ID: 16484290

  • 1. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.
    Milio G, Corrado E, Genova C, Amato C, Raimondi F, Almasio PL, Novo S.
    Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
    Kawald A, Burmester GR, Huscher D, Sunderkötter C, Riemekasten G.
    J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
    [Abstract] [Full Text] [Related]

  • 5. [Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis].
    Cordioli E, Virgilio S, Ghirardi R, Martinelli M.
    Minerva Med; 1992 Nov; 83(11):739-44. PubMed ID: 1281297
    [Abstract] [Full Text] [Related]

  • 6. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.
    Black CM, Halkier-Sørensen L, Belch JJ, Ullman S, Madhok R, Smit AJ, Banga JD, Watson HR.
    Br J Rheumatol; 1998 Sep; 37(9):952-60. PubMed ID: 9783759
    [Abstract] [Full Text] [Related]

  • 7. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.
    Scorza R, Caronni M, Mascagni B, Berruti V, Bazzi S, Micallef E, Arpaia G, Sardina M, Origgi L, Vanoli M.
    Clin Exp Rheumatol; 2001 Sep; 19(5):503-8. PubMed ID: 11579708
    [Abstract] [Full Text] [Related]

  • 8. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon.
    Bartolone S, Trifiletti A, De Nuzzo G, Scamardi R, Larosa D, Sottilotta G, Raffa A, Barbera N.
    Minerva Cardioangiol; 1999 May; 47(5):137-43. PubMed ID: 10479851
    [Abstract] [Full Text] [Related]

  • 9. [Treatment of Raynaud's phenomenon in scleroderma with a new stable prostacyclin derivative].
    Keller J, Kaltenecker A, Schricker KT, Krais T, Schönberger A, Gevatter M, Hornstein OP.
    Dtsch Med Wochenschr; 1984 Sep 21; 109(38):1433-8. PubMed ID: 6383760
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis.
    Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, Silman A.
    Cochrane Database Syst Rev; 2000 Sep 21; 1998(2):CD000953. PubMed ID: 10796395
    [Abstract] [Full Text] [Related]

  • 12. Outpatient treatment of severe peripheral ischemia with intravenous intermittent low-dose iloprost. An open pilot study.
    Banyai S, Jenelten R, Wagner S, Allmann J, Banyai M, Koppensteiner R.
    Int Angiol; 2002 Mar 21; 21(1):36-43. PubMed ID: 11941272
    [Abstract] [Full Text] [Related]

  • 13. [Iloprost for the treatment of systemic sclerosis].
    Hachulla E, Launay D, Hatron PY.
    Presse Med; 2008 May 21; 37(5 Pt 2):831-9. PubMed ID: 18035518
    [Abstract] [Full Text] [Related]

  • 14. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R, Shariat K, von Wilmowsky H, Böhm M.
    Circulation; 2005 Nov 08; 112(19):2980-5. PubMed ID: 16275885
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of iloprost for the treatment of ischaemic digits in paediatric connective tissue diseases.
    Zulian F, Corona F, Gerloni V, Falcini F, Buoncompagni A, Scarazatti M, Martini G, Zacchello F.
    Rheumatology (Oxford); 2004 Feb 08; 43(2):229-33. PubMed ID: 12923288
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Is iloprost effective in secondary Raynaud's phenomenon?
    Lustig N, Rada G.
    Medwave; 2015 Mar 09; 15(2):e6082. PubMed ID: 25826330
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
    Rosato E, Letizia C, Proietti M, Aversa A, Menghi G, Rossi C, Torella E, Cotesta D, Petramala L, Bruzziches R, Spera G, Pisarri S, Salsano F.
    J Biol Regul Homeost Agents; 2009 Mar 09; 23(1):23-9. PubMed ID: 19321043
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.